President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

Inspired by his famous sisters, 1000-lb Sisters star Chris Combs decided to go on his own weight loss journey. How did losing ...

Studies in neuroscience with applications to humans offer clues about what makes us start eating, and when we stop.

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.85, a high estimate of $68.00, ...

In the latest market close, Hims & Hers Health, Inc. (HIMS) reached $28.10, with a -0.14% movement compared to the previous day. This change lagged the S&P 500's daily gain of 0.74%. Elsewhere, the ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Jelly Roll continues to do what's been working for him when it comes to losing weight. On the Thursday, April 24, episode of ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...

Citi lowered the firm’s price target on Hims & Hers to $25 from $27 and keeps a Sell rating on the shares. The firm also added a “downside ...

Hims & Hers (HIMS) stock in focus as a U.S. court denies injunction to continue making cheap versions of Novo Nordisk's (NVO) ...